Sign in
Taking people in United StatesNo phase

Tracks muscle changes in people with type 2 diabetes and obesity taking semaglutide

Uses MRI scans to track muscle changes during semaglutide treatment.

Key facts

Who runs it
The Cleveland Clinic
Where
Cleveland, United StatesSee the site
Trial code
Registry title
Imaging in Semaglutide Study
Status
Recruiting
People taking part
10 people, planned
Started
30 Jul 2026
Expected to end
1 Jun 2027
Type of study
Observational
Treatments tested
  • 31P-MRS and MRI
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and obesity who are about to start semaglutide injections. Scans and strength tests follow their muscles over 6 months.

Age
45 to 75 years
Sex
Men and women
Disease stage
Type 2 diabetes with HbA1c between 7% (53 mmol/mol) and 10.5% (91 mmol/mol), and BMI of at least 30 and below 45 kg/m2.
Earlier treatment
Must be starting subcutaneous semaglutide for type 2 diabetes. Cannot have had weight-loss medicine in the 90 days before screening. Cannot have had bariatric or metabolic surgery.
Biomarker or test result
HbA1c between 7% (53 mmol/mol) and 10.5% (91 mmol/mol). A recent eGFR result from the past 120 days must be available.

Main reasons for not taking part

  • Allergy or past intolerance to semaglutide, any GLP-1RA or GIP/GLP-1RA
  • Cannot have an MRI (for example a pacemaker, claustrophobia, or a calf wider than 43 cm (17 in))
  • Heart attack or heart procedure in the past 30 days, or hospital stay for heart failure in the past 30 days
  • Pregnant, planning pregnancy in the next 12 months, or breastfeeding
  • Active smoking or 3 or more alcoholic drinks per day

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • Gender: men and women
  • Ethnicity: all ethnic groups
  • Age between 45 and 75 years
  • BMI ≥ 30 kg/m2 and BMI < 45 kg/m2
  • Diagnosis of Type 2 Diabetes (T2D) with HbA1c levels between 7% and 10.5%
  • Starting subcutaneous semaglutide for clinically indicated T2D management
  • Ability and willingness to participate in the study for its full duration
  • Provision of informed consent for participation in research

Who cannot take part

  • Previous intolerance or allergy to any semaglutide-based therapy
  • History of prior intolerance to any GLP-1RA or GIP/GLP-1RA
  • History of myocardial infarction or coronary revascularization (percutaneous intervention or coronary artery bypass) within 30 days prior to screening
  • Current use of glucocorticoid therapy (≥5 mg prednisone or equivalent)
  • Self-reported weight loss > 10 lbs in the 90 days prior to screening
  • Use of other mediation, on or off-label, for the primary intent of weight loss within 90 days prior to screening
  • Prior participation in the Endocrinology and Metabolism Institute's Integrated Weight Management Program within the past 3 months
  • Major surgical procedures or significant traumatic injury within 30 days prior to the enrollment date
  • Contraindication to MRI (e.g. claustrophobia, implanted devices including cardiac pacemaker and cardioverter-defibrillators), circumference of largest calf > 17inch/43cm (max size to fit into the MR coil)
  • History of hospitalization for heart failure within the past 30 days, or NYHA class IV
  • Secondary etiologies for sarcopenia (e.g., gastrointestinal malabsorption, myopathies, severe neurological conditions)
  • History of bariatric or metabolic surgery or related procedures
  • Uncontrolled lung disease (e.g., severe asthma or COPD)
  • Uncontrolled thyroid disease
  • History of malabsorptive disorders, such as celiac disease or Crohn's disease
  • Conductive implanted devices (e.g., cardiac pacemaker, cardioverter-defibrillators)
  • Any medical or surgical condition that, in the opinion of the principal investigator, may make the participant unfit for the trial (e.g., psychiatric disorders, malignancy)
  • Any condition, unwillingness, or inability, not otherwise covered by exclusion criteria, which might jeopardize the subject's safety or compliance with the protocol
  • Glomerular Filtration Rate (eGFR) within the past 120 days is not available
  • Cholestatic liver disease or inadequate hepatic function (AST/ALT > 3.0 x ULN)
  • Unwillingness or uncertainty to commit to the duration of the study
  • Mental incapacity or language barriers preventing informed consent and compliance
  • Pregnancy, plans for pregnancy in the next 12 months, or lactating/nursing females
  • Active smoking
  • Excessive alcohol consumption, defined as ≥3 drinks per day
  • Personal commitments that may limit optimal participation (e.g., work, travel, caregiving responsibilities)
  • Liver cirrhosis
  • Presence of metal in the eye

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 45 and 75 years old?

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Andrea ParianosTaking people

About the trial

What the trial wants to find out

In this preliminary observation study, the investigators will assess muscle function in terms of muscle strength and leverage imaging (MRI) and spectroscopy (31P-MRS) based techniques to assess longitudinal changes in muscle volume, quality and metabolic function in patients with T2D and obesity prescribed to semaglutide therapy. The patients will be evaluated at three time points: 1) baseline, 2) 3-month and 3) 6-month after the therapy. These longitudinal changes will then be compared and correlated with changes in physical measurements such as BMI and patient reported outcome measures (PROMs). The primary aim of our study is to investigate the longitudinal effects of semaglutide therapy on patients with T2D and obesity, on skeletal muscle strength, muscle volume, quality and metabolic function.

Treatments tested

  • 31P-MRS and MRI

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
31P-MRS and MRI Imaging in Semaglutide Study
Plain-language title
Tracks muscle changes in people with type 2 diabetes and obesity taking semaglutideGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07695454, who can take part
Record updated
6 October 2026